小胶质细胞活化在视网膜色素变性中的调控机制研究进展  

Research progress of microglia activation in the regulatory mechanism of retinitis pigmentosa

作　　者：周维 梁丽娜[1] ZHOU Wei;LIANG Lina(Department of Eye Function Laboratory,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)

机构地区：[1]中国中医科学院眼科医院眼功能实验室,北京市100040

出　　处：《眼科新进展》2024年第2期159-163,共5页Recent Advances in Ophthalmology

基　　金：国家自然科学基金资助(编号:82274589,81973912);首都卫生发展科研专项项目(编号:首发2020-2-4183);中国中医科学院科技创新工程(编号:CI2021A02602)。

摘　　要：视网膜色素变性(RP)是一种遗传性视网膜退行性眼病,越来越多的研究表明,视网膜变性早期发现小胶质细胞(MG)的活化反应。作为中枢神经系统和视网膜的免疫细胞,MG在体内参与先天性免疫系统第一道防线的形成,在多种神经退行性病变过程中具有神经保护或神经毒性作用。MG活化后产生的神经毒性或神经保护作用可影响RP的病理进程。因此,围绕以MG为靶点的治疗策略,通过平衡神经保护或神经毒性作用,从而影响疾病进程和转归,可能是未来的治疗方向。Retinitis pigmentosa(RP)is a hereditary retinal degenerative ocular disease.Accumulating studies have demonstrated that microglia(MG)activation occurs at the early stage of retinal degeneration.MG,as immune cells in the central nervous system and retina,are involved in the formation of the front line of the innate immune system,exhibiting neuroprotective or neurotoxic effects in various neurodegenerative processes.The neurotoxic or neuroprotective effects resulting from microglia activation may influence the pathological progression of RP.Consequently,therapeutic strategies targeting MG,aiming to modulate disease progression and outcome by balancing neuroprotective or neurotoxic effects,represent a promising avenue for future treatment.

关 键 词：小胶质细胞 活化 视网膜色素变性 调控机制 

分 类 号：R774.1[医药卫生—眼科]